Table 4 Primary and secondary outcomes in male and female patients in tranexamic acid after PSM
Outcomes | After PSM | After Logistic regression | ||||
|---|---|---|---|---|---|---|
Female (n = 6808) | Male (n = 6808) | OR (95%CI) | p value | β (95% CI) | p value | |
Primary outcome | ||||||
RBC, n (%) | 2246(33.0) | 1469(21.6) | 1.53 (1.43–1.63) | < 0.0001 | 2.12 (1.98–2.27) | < 0.0001 |
Secondary outcome | ||||||
FFP, n (%) | 689(10.1) | 1088(16.0) | 0.63(0.58–0.70) | < 0.0001 | 0.60(0.55–0.66) | < 0.0001 |
PLT, n (%) | 181(2.7) | 155(2.3) | 1.17(0.94–1.45) | 0.156 | 1.35(1.11–1.64) | 0.003 |
Reoperation due to major hemorrhage or cardiac tamponade, n (%) | 88(1.3) | 137(2.0) | 0.64(0.49–0.84) | 0.001 | 0.67(0.53–0.85) | 0.001 |
Blood loss in 24 h after surgery (mL), median (IQR) | 360(260–490) | 460(330–610) | < 0.0001 | − 106.61(− 114.33 ~ − 98.89) | < 0.0001 | |
Blood loss in 48 h after surgery (ml), median (IQR) | 580(440–760) | 730(550–940) | < 0.0001 | − 156.18(− 166.69 ~ − 145.67) | < 0.0001 | |
Total Blood loss after surgery(ml), median (IQR) | 760(570–1070) | 940(700–1310) | < 0.0001 | − 206.33(− 228.66 ~ − 184.00) | < 0.0001 | |